The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
Abstract
Objective: To assess the efficacy of anakinra treatment in patients with adult‐onset Still's disease (AOSD) that is refractory to corticosteroids, methotrexate (MTX), and etanercept. Methods: Four patients with AOSD were treated with prednisone and MTX and 2 patients were also treated with etanercept for worsening symptoms and indicators of systemic inflammation. White blood cells (WBCs), C‐reactive protein (CRP) levels and/or erythrocyte sedimentation rate, and ferritin levels were measured and, in 1 patient, serum creatinine levels were determined. Treatment with anakinra at 100 mg/day was initiated. Results: The index patient's disease was refractory to treatment with prednisone (30 mg/day) and MTX, with spiking fevers, rash, synovitis, a serum ferritin level of 8,400 ng/ml (normal ≤200), and a CRP level of 86 mg/liter (normal <8). Levels of interleukin‐1β (IL‐1β), IL‐1α, IL‐6, IL‐1 receptor antagonist, and IL‐18 were elevated. Just prior to anakinra treatment, the WBC count was 14,600/mm 3, the CRP level was 86 mg/liter, and the ferritin level was 573 ng/ml, with daily spiking fevers to 104°F, rash, and swollen joints. Within hours of the first injection, the patient was afebrile and asymptomatic; within days, the WBC count, ferritin level, and CRP level decreased into the normal range. On 2 occasions, anakinra was withheld. Within a few days, the WBC count rose to >20,000/mm 3 with prominent neutrophilia, the CRP level rose to >200 mg/liter, and the ferritin level rose to >3,000 ng/ml. Upon restarting anakinra, the patient became afebrile, the WBC count fell to 8,000/mm 3, the CRP level fell to <3 mg/liter, and the ferritin level fell to <300 ng/ml. Three additional patients with refractory AOSD who experienced rapid reductions in fever, symptoms, and markers of inflammation when treated with anakinra are reported. Conclusion: Refractory AOSD appears to be IL‐1–mediated since anakinra decreases hematologic, biochemical, and cytokine markers and also produces rapid reductions in systemic and local inflammation. Reported efficacy of tumor necrosis factor–blocking therapies in AOSD may be due to a reduction in IL‐1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Self-citationTuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Preliminary criteria for classification of adult Still's disease.
Yamaguchi, M., Ohta, A., Tsunematsu, T., Kasukawa, R., Mizushima, Y., Kashiwagi, H., Kashiwazaki, S., Tanimoto, K., Matsumoto, Y., & Ota, T. (1992) · PubMed · Cited by 1,788
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.
Dinarello, C. A., Cannon, J. G., Wolff, S. M., Bernheim, H. A., Beutler, B., Cerami, A., Figari, I. S., Palladino, M. A., & O'Connor, J. V. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.6.1433 · Cited by 1,472
Self-citationGranulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.
Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., & Costantini, F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06368.x · Cited by 749
Spectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Aksentijevich, I., Nowak, M., Mallah, M., Chae, J. J., Watford, W. T., Hofmann, S. R., Stein, L., Russo, R., Goldsmith, D., Dent, P., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10688 · Cited by 709
Interleukin-1–Receptor Antagonist in the Muckle–Wells Syndrome
Hawkins, P. N., Lachmann, H. J., & McDermott, M. F. (2003) · New England Journal of Medicine · doi:10.1056/nejm200306193482523 · Cited by 654
Fong, Y., Tracey, K. J., Moldawer, L. L., Hesse, D. G., Manogue, K. B., Kenney, J. S., Lee, A. T., Kuo, G. C., Allison, A. C., & Lowry, S. F. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.5.1627 · Cited by 641
Hoffman, H. M., Rosengren, S., Boyle, D. L., Cho, J. Y., Nayar, J., Mueller, J. L., Anderson, J. P., Wanderer, A. A., & Firestein, G. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17401-1 · Cited by 552
Charles, P. J., Elliott, M. J., Davis, D., Potter, A. R., Kalden, J. R., Antoni, C., Breedveld, F. C., Js, S., Eberl, G., DeWoody, K. L., et al. (1999) · PubMed · Cited by 531
Defective inflammatory response in interleukin 6-deficient mice.
Fattori, E., Cappelletti, M., Costa, P., Sellitto, C., Cantoni, L., Carelli, M., Faggioni, R., Fantuzzi, G., Ghezzi, P., & Poli, V (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1243 · Cited by 525
Toward an Epidemiology and Natural History of SIRS (Systemic Inflammatory Response Syndrome)
Bone, R. C. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490240060037 · Cited by 513
Fisher, C. J., Slotman, G. J., Opal, S. M., Pribble, J. P., Bone, R. C., Emmanuel, G., Ng, D., Bloedow, D. C., & Catalano, M. A. (1994) · Critical Care Medicine · doi:10.1097/00003246-199401000-00008 · Cited by 490
Charles, P., Elliott, M. J., Davis, D., Potter, A., Kalden, J. R., Antoni, C., Breedveld, F. C., Smolen, J. S., Eberl, G., deWoody, K., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1521 · Cited by 436
Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
Resistance to fever induction and impaired acute-phase response in interleukin-1β-deficient mice
Zheng, H., Fletcher, D., Kozak, W., Jiang, M., Hofmann, K. J., Corn, C. A., Soszynski, D., Grabiec, C., Trumbauer, M. E., Shaw, A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90154-x · Cited by 365
The precursor form of IL-1α is an intracrine proinflammatory activator of transcription
Werman, A., Werman-Venkert, R., White, R., Lee, J.-K., Werman, B., Krelin, Y., Voronov, E., Dinarello, C. A., & Apte, R. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308705101 · Cited by 346
Self-citationChai, Z., Gatti, S., Toniatti, C., Poli, V, & Bartfai, T. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.311 · Cited by 343
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
Pusztai, L., Mendoza, T. R., Reuben, J. M., Martinez, M. M., Willey, J. S., Lara, J., Syed, A., Fritsche, H. A., Bruera, E., Booser, D., et al. (2004) · Cytokine · doi:10.1016/j.cyto.2003.10.004 · Cited by 312
Pomerantz, B. J., Reznikov, L. L., Harken, A. H., & Dinarello, C. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041611398 · Cited by 310
Self-citationA NOVEL IL-18BP ELISA SHOWS ELEVATED SERUM IL-18BP IN SEPSIS AND EXTENSIVE DECREASE OF FREE IL-18
Novick, D., Schwartsburd, B., Pinkus, R., Suissa, D., Belzer, I., Sthoeger, Z., Keane, W. F., Chvatchko, Y., Kim, S.-H., Fantuzzi, G., et al. (2001) · Cytokine · doi:10.1006/cyto.2001.0914 · Cited by 277
Self-citationKawashima, M., Yamamura, M., Taniai, M., Yamauchi, H., Tanimoto, T., Kurimoto, M., Miyawaki, S., Amano, T., Takeuchi, T., & Makino, H. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200103)44:3<550::aid-anr103>3.0.co;2-5 · Cited by 268
Lovell, D. J., Giannini, E. H., Reiff, A., Jones, O. Y., Schneider, R., Olson, J. C., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10710 · Cited by 250
Feinberg, B., Kurzrock, R., Talpaz, M., Blick, M., Saks, S., & Gutterman, J. U. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.8.1328 · Cited by 221
Pathogenesis of hemophagocytic syndrome (HPS)
Larroche, C., & Mouthon, L. (2004) · Autoimmunity Reviews · doi:10.1016/s1568-9972(03)00091-0 · Cited by 221
Sherman, M. L., Spriggs, D. R., Arthur, K. A., Imamura, K., Frei, E., & Kufe, D. W. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.344 · Cited by 215
Michel, M., Duvoux, C., Hézode, C., & Cherqui, D. (2003) · PubMed · Cited by 201
Serum cytokine profiles in patients with adult onset Still's disease.
Choi, J., Suh, C., Lee, Y. M., Suh, Y.-J., Lee, S.-K., Kim, S.-S., Nahm, D. H., & Park, H. (2003) · PubMed · Cited by 197
IL‐6 and IL‐1β in Fever: Studies Using Cytokine‐Deficient (Knockout) Mice a
KOZAK, W., KLUGER, M. J., SOSZYNSKI, D., CONN, C. A., RUDOLPH, K., LEON, L. R., & ZHENG, H. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb08310.x · Cited by 189
Beneficial response to interleukin 1 receptor antagonist in traps
Simon, A., Bodar, E. J., van der Hilst, J. C. H., van der Meer, J. W. M., Fiselier, T. J. W., Cuppen, M. P. J. M., & Drenth, J. P. H. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.039 · Cited by 164
Smith, J. W., Urba, W. J., Curti, B. D., Elwood, L. J., Steis, R. G., Janik, J. E., Sharfman, W. H., Miller, L. L., Fenton, R. G., & Conlon, K. C. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1141 · Cited by 162
Crown, J. P., Jakubowski, A. A., Kemeny, N. E., Gordon, M. S., Gasparetto, C., Wong, G. G., Sheridan, C., Toner, G. C., Meisenberg, B., & Botet, J. F. (1991) · Blood · doi:10.1182/blood.v78.6.1420.1420 · Cited by 142
The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin
Smith, J. W., Longo, D. L., Alvord, W. G., Janik, J. E., Sharfman, W. H., Gause, B. L., Curti, B. D., Creekmore, S. P., Holmlund, J., Fenton, R. G., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303183281103 · Cited by 138
Effects on leukocytes after injection of tumor necrosis factor into healthy humans
van der Poll, T., van Deventer, S. J. H., Hack, C. E., Wolbink, G., Aarden, L. A., Buller, H. R., & ten Cate, J. W. (1992) · Blood · doi:10.1182/blood.v79.3.693.693 · Cited by 128
Fisher, C. J., MARRA, M. N., Palardy, J. E., et al. (1994) · Critical Care Medicine · doi:10.1097/00003246-199404000-00008 · Cited by 122
Iwamoto, M., Nara, H., Hirata, D., Minota, S., Nishimoto, N., & Yoshizaki, K. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10620 · Cited by 118
A phase I clinical trial of recombinant human tumor necrosis factor
Creagan, E. T., Kovach, J. S., Moertel, C. G., Frytak, S., & Kvols, L. K. (1988) · Cancer · doi:10.1002/1097-0142(19881215)62:12<2467::aid-cncr2820621202>3.0.co;2-5 · Cited by 116
Association between adult-onset Still's disease and interleukin-18 gene polymorphisms
Sugiura, T., Kawaguchi, Y., Harigai, M., Terajima-Ichida, H., Kitamura, Y., Furuya, T., Ichikawa, N., Kotake, S., Tanaka, M., Hara, M., et al. (2002) · Genes and Immunity · doi:10.1038/sj.gene.6363922 · Cited by 115
Serum IL-1β levels in health and disease: a population-based study. ‘The InCHIANTI study’
Iorio, A. D., Ferrucci, L., Sparvieri, E., Cherubini, A., Volpato, S., Corsi, A., Bonafè, M., Franceschi, C., Abate, G., & Paganelli, R. (2003) · Cytokine · doi:10.1016/s1043-4666(03)00152-2 · Cited by 108
Infliximab in the treatment of adult Still's disease refractory to conventional therapy.
Cavagna, L., Caporali, R. F., Epis, O. M., Bobbio‐Pallavicini, F., & Montecucco, C. (2001) · PubMed · Cited by 98
Kokkinos, A. D., Iliopoulos, A., Greka, P., et al. (2004) · Clinical Rheumatology · doi:10.1007/s10067-003-0775-5 · Cited by 96
Maeno, N., Takei, S., Imanaka, H., Yamamoto, K., Kuriwaki, K., Kawano, Y., & Oda, H. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20268 · Cited by 91
Li, S., Goorha, S., Ballou, L. R., & Blatteis, C. M. (2003) · Brain Research · doi:10.1016/j.brainres.2003.08.033 · Cited by 64
Ogilvie, A. C., Hack, C. E., Wagstaff, J., van Mierlo, G. J., Erenberg, A. J., Thomsen, L. L., Hoekman, K., & Rankin, E. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.389 · Cited by 54
Anakinra for the treatment of adult-onset Still’s disease
Castañeda, S., Atienza‐Mateo, B., Martín-Varillas, J. L., López-Matencio, J. M. S., & González-Gay, M. Á. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1536548 · Cited by 45
Physiological and cytokine responses in IL-1 beta-deficient mice after zymosan-induced inflammation
Fantuzzi, G., Sacco, S., Ghezzi, P., & Dinarello, C. A. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.273.1.r400 · Cited by 40
Self-citationInterleukin-1: Biological Effects in Human Hematopoiesis
Crown, J., Jakubowski, A. A., & Gabrilove, J. L. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309145750 · Cited by 38
Hm, L., Winton, E. F., Sf, W., Grinblatt, D. L., Campion, M., Cooper, B., Gunn, H., Manfreda, S., & Isaacs, R. E. (1995) · PubMed · Cited by 35
Role of interleukin-1 in hematopoiesis
Moore, M. A. S. (1989) · Immunologic Research · doi:10.1007/bf02918142 · Cited by 34
Human herpesvirus 6 and adult-onset Still’s disease
Daibata, M., & Taguchi, H. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01238-x · Cited by 16
Cited by
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Self-citationOverview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Self-citationTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Self-citationAnti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Self-citationInterleukin-18 and IL-18 Binding Protein
Dinarello, C. A., Novick, D., Kim, S., & Kaplanski, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00289 · Cited by 938
Self-citation
Metadata
- Authors
- Fitzgerald, A. A., LeClercq, S. A., Yan, A., Homik, J. E., & Dinarello, C. A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-06
- Volume
- 52
- Issue
- 6
- Pages
- 1794-1803
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2048698451
- Cited by
- 350
- References
- 54
- FWCI
- 18.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.